




















 



 Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer 
         










    










 






 











 









Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer

Jan 08, 2014, 08:00 ET
		  		  					
						 from   Kite Pharma, Inc. 











 
















































 

 















































 

 

 
 
 
 







Kite Pharma, Inc.'s logo.  (PRNewsFoto/Kite Pharma, Inc.)    
 Facebook
 Twitter
 Pinterest

































 




 




Kite Pharma, Inc.'s logo.  (PRNewsFoto/Kite Pharma, Inc.)
 


 

 




 





 


LOS ANGELES, Jan. 8, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Officer.  A veteran financial and operational executive, Ms. Butitta brings over 20 years' experience in leadership roles in the biotech and technology industries.  Her appointment is effective immediately.
(Logo: http://photos.prnewswire.com/prnh/20130513/MM13332LOGO)
Arie Belldegrun, M.D., Founder and Executive Chairman of the Board of Kite Pharma, commented, "Cindy has an outstanding track record and depth and breadth of experience in capital fund raising, strategic planning and investor relations at both private and public biotechnology companies.  We are delighted to welcome her to the team and believe her unique capabilities and expertise will greatly benefit Kite as we pursue our clinical and business objectives."
Prior to joining Kite, Ms. Butitta served as Senior Vice President, Chief Financial Officer of NextWave Pharmaceuticals.  During her tenure, Ms. Butitta was responsible for finance and administration, distribution and project management and played a key role in the Company's acquisition by Pfizer, Inc. for $700 million.  Previously, she was Chief Financial Officer and Chief Operating Officer of Telik, Inc.  At Telik, Ms. Butitta was responsible for securing over $450 million through an IPO and subsequent follow-on offerings and oversaw financial reporting and controls, investor relations, information technology, manufacturing, quality, project management and commercial operations.  Previously, she served as Vice President of Finance and Administration and Chief Financial Officer for Connetics, Inc., a public biotechnology company.  Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and her MBA degree in Finance from the University of Wisconsin, Madison.
Ms. Butitta stated, "I am thrilled to join the accomplished executive management team at Kite.  As a leading company in the emerging and highly promising field of immunotherapy, Kite has the opportunity to play a pivotal role in changing the way we approach cancer.  It is an exciting time for the Company, with recent clinical breakthroughs reported at a major cancer conference, and I look forward to contributing to Kite's continued evolution and growing presence within the life sciences industry."
About Kite Pharma
Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA.  For more information, visit the company's website at http://www.kitepharma.com.
Kite Contact:Dr. Arie BelldegrunExecutive Chairman310-824-9999arie@kitepharma.com
For Media:Justin JacksonBurns McClellan(212) 213-0006jjackson@burnsmc.com
 SOURCE  Kite Pharma, Inc.  

RELATED LINKS
http://www.kitepharma.com



  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  











Jan 17, 2014, 08:00 ET
Preview: Kite Pharma Appoints Rizwana F. Sproule, Ph.D., as Vice President, Regulatory Affairs


















Jan 07, 2014, 08:00 ET
Preview: Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference








My News


  Release contains wide tables.	  View fullscreen.





Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 




Cynthia M. Butitta – Kite Pharma


































 
MENU
Toggle navigation



Investors/Media
Careers
Contact Us
Home
About Us 

Our Mission
Management Team
Board of Directors
Scientific Advisory Board


Research 

Our Research
Technology
Pipeline
Clinical Trials
Expanded Access


Collaborations 

Our Collaborations
Joint Ventures
Strategic Collaborations
CAR
TCR
Enabling Technologies


Kite World
Careers
Investor Relations 

Investor Relations
Press Releases
Events & Presentations
Corporate Governance
— Management Team
— Board of Directors
— Committee Composition
— Contact the Board
Financials & Filings
— SEC Filings
— Annual Reports & Proxies
— Quarterly Results
— Key Ratios
Stock Information
— Historic Stock Lookup
— Investment Calculator
— Dividend History
— Analyst Coverage
Investor FAQs


Contact Us
 






Kite World>

Cynthia M. Butitta 












Cynthia M. Butitta: Executive Profile & Biography - Bloomberg










































  





















































































July 22, 2017 10:43 AM ET
Biotechnology

Company Overview of Kite Pharma, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Cynthia M. Butitta  Chief Operating Officer, Kite Pharma, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.62$4,570,596As of Fiscal Year 2016
Background

		Ms. Cynthia M. Butitta has been the Chief Operating Officer of Kite Pharma, Inc. since March 2014. Ms. Butitta has been the Chief Financial Officer and Senior Vice President of NextWave Pharmaceuticals, Inc. since May 2011. She served as the Chief Financial Officer of Kite Pharma, Inc. from January 8, 2014 to May 2016. Ms. Butitta served as an Executive Vice President of Kite Pharma, Inc. She is an experienced fiscal and operational executive with more than 20 years ... of leadership in both the biotechnology and high-technology industries. Prior to joining NextWave, Ms. Butitta served as Chief Operating Officer of Telik Inc. from March 2001 to December 22, 2010 and its Chief Financial Officer from August 1998 to December 22, 2010. Ms. Butitta also served as Principal Accounting Officer of Telik, Inc. until December 22, 2010. From September 1997 to February 2001, she also provided financial consulting services as a partner in Altair Capital Associates LLC, which she co-founded in November 1998 and Butitta consulting Services LLC, which she founded in September 1997. From December 1995 to September 1997, Ms. Butitta served as Vice President of Finance and Administration and the Chief Financial Officer for Connetics, Inc., a biotechnology company. From June 1994 to December 1995, Ms. Butitta was the Vice president of Finance and Administration and the Chief Financial Officer of Insite Vision, Inc., a biotechnology company. She served as a Director of Catalyst Semiconductor Inc., a semiconductor products company, from June 2000 to February 25, 2003. Ms. Butitta holds a B.S. degree in Business and Accounting from Edgewood College in Madison, Wisconsin and an MBA degree in Finance from the University of Wisconsin, Madison.Read Full Background




Corporate Headquarters
2225 Colorado AvenueSanta Monica, California 90404United StatesPhone: 310-824-9999Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
MBA University of Wisconsin - MadisonBS Edgewood College
Other Affiliations
Telik Inc.Catalyst Semiconductor, Inc.University of Wisconsin - MadisonEdgewood CollegeNextWave Pharmaceuticals Incorporated


Annual Compensation
Salary$490,000Total Annual Compensation$490,000
Stocks Options
Restricted Stock Awards$1,143,032All Other Compensation$7,950Exercised Options$100,000Exercised Options Value$5,025,957Exercisable Options$385,977Exercisable Options Value$12,925,460Unexercisable Options$339,480Unexercisable Options Value$6,208,185Total Value of Options$24,159,601Total Number of Options$825,457
Total Compensation
Total Annual Cash Compensation$742,950Total Short Term Compensation$490,000Other Long Term Compensation$1,150,982Total Calculated Compensation$4,570,596




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationRandal J. Kirk J.D.Chairman and Chief Executive OfficerIntrexon Corporation--Compensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Kite Pharma, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close
































Butitta, Cynthia M. - The Wall Street Transcript













































 





































Cynthia M. Butitta
Cynthia M. Butitta is Telik’s Chief Operating Officer and Chief Financial Officer. She joined the company in 1998 as Chief Financial Officer. Ms. Butitta has extensive financial and operational experience in the biotechnology and high technology industries. Prior to joining Telik, she provided financial and consulting services to biotechnology companies as a Partner in Altair Capital Associates, and she also operated Butitta Consulting Services. From 1995 to 1997, Ms. Butitta was Vice President of Finance and Administration, and Chief Financial Officer for Connetics, Inc. Previously, she was Director of Sales Operations for MIPS Computer Systems, Inc., and she has held senior level positions in information technology, contract planning and manufacturing in the high technology industry. Ms. Butitta holds a B.S. in business and accounting from Edgewood College in Madison, Wis., and an MBA in finance from the University of Wisconsin, Madison.
Dr. Michael M. Wick, M.D., Ph.D., is Chairman and Chief Executive Officer of Telik, Inc. He joined Telik in 1997 from CV Therapeutics, Inc., where he was Senior Vice President of Research and Development. Prior to joining CV Therapeutics, Dr. Wick was Executive Director of Oncology/Immunology and Clinical Research at Lederle Laboratories, a division of American Cyanamid, where he also directed the Cyanamid/Immunex joint oncology research program. Dr. Wick began his career at Harvard Medical School, where he was an Associate Professor. He also was Chief of the Melanoma Clinic and Laboratory of Molecular Dermatological Oncology at the Dana Farber Cancer Institute. Dr. Wick holds a Ph.D. in chemistry from Harvard University and an M.D. from Harvard Medical School.
Related Interviews:Telik, Inc. - Dr. Michael M. Wick And Cynthia M. ButittaNovember 02, 2009







CartLatest NewsJames Abate of Centre Asset Management Sees Consumer Demand Driving New Stock HighsMalcolm E. Polley of Stewart Capital and How to Play the Health Care StocksTimothy Biltz, CEO of Lumos Networks Identifies the Key Component for Future 5G NetworksThe Wall Street Transcript is a completely unique resource for investors and business researchers.Over 20,000 CEO, Equity Analyst and Money Manager InterviewsSubscribe now!Sign Up For Newsletter Weekly email with New In-Depth Interviews


Email: 



Most Popular InterviewsDelivering Long-Term Results with a Risk-Managed Growth FundJames A. Abate Published July 20, 2017 in Investing StrategiesCompanies covered: AMAT JNJ COH RL COG NVDA ADBE ATVI KLAC AMZN NFLX GOOG FB GLW MU 005930 000660 WFM JWN CMG GPS EQT RICE SPLS Buy ($25)Finding Investments with Favorable Risk and Reward OpportunitiesHenry  Beukema Published July 19, 2017 in Investing StrategiesCompanies covered: ORCL MSFT NSRGY AMZN WFM LRLCY AGN LNR Buy ($25)Better Returns and Lower Risk in the Midcap SpaceMalcolm E. Polley Published July 18, 2017 in Investing StrategiesCompanies covered: PRAA HURN FII FL NKE AMZN WFM WBA RAD Buy ($25)Most Popular ReportsWireless Communications & Telecom Published July 14, 2017Buy ($175)Investing Strategies Published July 11, 2017Buy ($175)Investing Strategies Published June 30, 2017Buy ($175) 






Top Company Interviews






Register for a Free Account to gain greater access to
            The Wall Street Transcript right now




CEO INTERVIEWSInterview with the President and CEO: Lumos Networks Corp. (NASDAQ:LMOS)Interview with the Corporate VP of Business Development, Strategy and Investor Relations: DSP Group, Inc. (NASDAQ:DSPG)Interview with the CEO and Director: Tactile Systems Technology, Inc. (NASDAQ:TCMD) 

SECTOR ROUNDTABLESNatural Gas Weighs Heavy On E&P Near-Term ProspectsRoundtable Forum:optimism Despite Uncertainty In For-profit EducationRoundtable Forum:a Shift In Focus To Natural Gas From Oil 

MONEY MANAGER INTERVIEWSDelivering Long-Term Results with a Risk-Managed Growth FundFinding Investments with Favorable Risk and Reward OpportunitiesBetter Returns and Lower Risk in the Midcap Space 

ANALYST INTERVIEWSAnalyzing the Secular Drivers Within Communications Infrastructure and TelecomSatellite Companies Benefiting from Growth in Data TrafficIncreased Focus on Content as Consumers Shift to Digital Consumption 




Subscribe Today!







                Since 1963
                © The Wall Street Transcript 1997-2016
Terms and Conditions
Privacy Policy  
            





https://www.twst.com/wp-admin/admin-ajax.php

Pin It on Pinterest





































Share This





Twitter





Facebook





Google+





Gmail





LinkedIn








































×





Join now for free!
Already a member?






First Name 





Last Name 





Email address *








Create new account
 


or create an account with a social network.

Join with Facebook


Join with Twitter


Join with Google








Username or Email address: *





Password: *






LoginJoin now! | Forgot password?
 


or login using a social network


Log in with Facebook


Log in with Twitter


Log in with Google















KITE Cynthia M. Butitta Insider Trades for Kite Pharma Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Kite Pharma Inc.

                  NASDAQ: KITE
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Kite Pharma Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 6:27 p.m.


KITE

/quotes/zigman/34007722/composite


$
109.89




Change

+0.74
+0.68%

Volume
Volume 18,730
Quotes are delayed by 20 min








/quotes/zigman/34007722/composite
Previous close

$
			109.89
		


$
				109.15
			
Change

-0.74
-0.67%





Day low
Day high
$108.68
$110.44










52 week low
52 week high

            $39.82
        

            $110.44
        


















Insider Activity


Individual




Cynthia M. Butitta



Ms. Cynthia M. Butitta is Chief Operating Officer at Kite Pharma, Inc. and Founder at Butitta Consulting Services LLC. Ms. Butitta was previously employed as Chief Financial Officer & Senior Vice President by NextWave Pharmaceuticals, Inc., Chief Operating & Financial Officer by Telik, Inc., Partner by Altair Capital Associates LLC, Chief Financial Officer by Connective Therapeutics, Inc., and Chief Financial Officer & VP-Administration by InSite Vision, Inc. She also served on the board at Catalyst Semiconductor, Inc. She received her undergraduate degree from Edgewood College and an MBA from the University of Wisconsin.



Transactions


Date
Shares
Transaction
Value





07/10/2017
5,000


 
Disposition at $105.5 per share.


527,500


07/10/2017
1,100


 
Disposition at $102.81 per share.


113,091


07/10/2017
5,553


 
Disposition at $102.19 per share.


567,462


07/10/2017
3,347


 
Disposition at $101.06 per share.


338,248


07/10/2017
15,000


 
Derivative/Non-derivative trans. at $1.35 per share.


20,250


06/23/2017
2,050


 
Disposition at $101.19 per share.


207,440


06/23/2017
2,950


 
Disposition at $100.54 per share.


296,593


06/23/2017
5,000


 
Derivative/Non-derivative trans. at $1.35 per share.


6,750


06/09/2017
400


 
Disposition at $91.08 per share.


36,432


06/09/2017
1,698


 
Disposition at $89.76 per share.


152,413


06/09/2017
4,100


 
Disposition at $89.09 per share.


365,269


06/09/2017
2,502


 
Disposition at $87.8 per share.


219,676


06/09/2017
900


 
Disposition at $86.42 per share.


77,778


06/09/2017
400


 
Disposition at $84.81 per share.


33,924


06/09/2017
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


04/25/2017
3,742


 
Disposition at $82.87 per share.


310,100


04/25/2017
5,545


 
Disposition at $82.14 per share.


455,467


04/25/2017
5,713


 
Disposition at $80.89 per share.


462,125


04/25/2017
15,000


 
Derivative/Non-derivative trans. at $1.35 per share.


20,250


04/03/2017
100


 
Disposition at $84.22 per share.


8,422


04/03/2017
700


 
Disposition at $83.46 per share.


58,422


04/03/2017
2,400


 
Disposition at $82.38 per share.


197,712


04/03/2017
1,800


 
Disposition at $80.69 per share.


145,242


04/03/2017
5,000


 
Derivative/Non-derivative trans. at $1.35 per share.


6,750


03/27/2017
400


 
Disposition at $78.75 per share.


31,500


03/27/2017
4,925


 
Disposition at $78.1 per share.


384,643


03/27/2017
4,375


 
Disposition at $77.23 per share.


337,882


03/27/2017
300


 
Disposition at $75.74 per share.


22,722


03/27/2017
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


03/09/2017
8,991


 
Disposition at $81.2 per share.


730,070


03/09/2017
12,127


 
Disposition at $80.47 per share.


975,860


03/09/2017
21,118


 
Derivative/Non-derivative trans. at $1.35 per share.


28,509


03/01/2017
28,882


 
Disposition at $80.05 per share.


2,312,005


03/01/2017
28,882


 
Derivative/Non-derivative trans. at $1.35 per share.


38,990


02/27/2017
690


 
Disposition at $56.83 per share.


39,213


02/27/2017
1,900


 
Disposition at $56.29 per share.


106,951


02/27/2017
1,800


 
Disposition at $54.91 per share.


98,838


02/27/2017
1,210


 
Disposition at $53.98 per share.


65,316


02/27/2017
4,400


 
Disposition at $53.15 per share.


233,860


02/27/2017
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


01/31/2017
10,000


 
Disposition at $50.56 per share.


505,600


01/31/2017
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


01/06/2017
10,000


 
Disposition at $50.13 per share.


501,300


01/06/2017
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


12/22/2016
24,800


 
Award at $0 per share.


0


12/20/2016
2,482


 
Disposition at $50.86 per share.


126,235


11/25/2016
300


 
Disposition at $51.42 per share.


15,426


11/25/2016
9,700


 
Disposition at $50.37 per share.


488,589


11/25/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


11/10/2016
410


 
Disposition at $51.27 per share.


21,021


11/10/2016
9,590


 
Disposition at $50.62 per share.


485,446


11/10/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


09/26/2016
10,000


 
Disposition at $54.13 per share.


541,300


09/26/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


08/25/2016
2,500


 
Disposition at $59.02 per share.


147,550


08/25/2016
7,500


 
Disposition at $58.03 per share.


435,225


08/25/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


07/25/2016
10,000


 
Disposition at $50.94 per share.


509,400


07/25/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


06/27/2016
10,000


 
Disposition at $50.15 per share.


501,500


06/27/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


06/23/2016
10,000


 
Disposition at $51.28 per share.


512,800


06/23/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


04/04/2016
10,000


 
Disposition at $50 per share.


500,000


04/04/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


03/01/2016
10,000


 
Disposition at $50.03 per share.


500,300


03/01/2016
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


02/02/2016
1,900


 
Disposition at $50.13 per share.


95,247


02/02/2016
1,900


 
Derivative/Non-derivative trans. at $1.35 per share.


2,565


01/27/2016
100


 
Disposition at $53.12 per share.


5,312


01/27/2016
2,800


 
Disposition at $52.91 per share.


148,148


01/27/2016
2,700


 
Disposition at $51.34 per share.


138,618


01/27/2016
2,500


 
Disposition at $50.42 per share.


126,050


01/27/2016
8,100


 
Derivative/Non-derivative trans. at $1.35 per share.


10,935


12/28/2015
2,710


 
Disposition at $61.99 per share.


167,993


12/28/2015
7,290


 
Disposition at $61.4 per share.


447,606


12/28/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


12/17/2015
18,500


 
Award at $0 per share.


0


11/27/2015
2,600


 
Disposition at $86.9 per share.


225,940


11/27/2015
12,400


 
Disposition at $86.35 per share.


1,070,740


11/27/2015
15,000


 
Derivative/Non-derivative trans. at $1.35 per share.


20,250


11/10/2015
5,000


 
Disposition at $80 per share.


400,000


11/10/2015
5,000


 
Derivative/Non-derivative trans. at $1.35 per share.


6,750


10/27/2015
500


 
Disposition at $71.01 per share.


35,505


10/27/2015
4,400


 
Disposition at $70.23 per share.


309,012


10/27/2015
5,100


 
Disposition at $69.53 per share.


354,603


10/27/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


09/28/2015
3,640


 
Disposition at $56.7 per share.


206,388


09/28/2015
3,560


 
Disposition at $55.91 per share.


199,040


09/28/2015
2,800


 
Disposition at $54.73 per share.


153,244


09/28/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


08/27/2015
1,600


 
Disposition at $54.38 per share.


87,008


08/27/2015
6,300


 
Disposition at $53.73 per share.


338,499


08/27/2015
2,100


 
Disposition at $52.69 per share.


110,649


08/27/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


07/27/2015
4,238


 
Disposition at $68.96 per share.


292,253


07/27/2015
5,762


 
Disposition at $68.13 per share.


392,566


07/27/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


06/29/2015
1,200


 
Disposition at $60.78 per share.


72,936


06/29/2015
5,000


 
Disposition at $59.98 per share.


299,900


06/29/2015
3,800


 
Disposition at $58.87 per share.


223,706


06/29/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


05/27/2015
100


 
Disposition at $51.16 per share.


5,116


05/27/2015
100


 
Disposition at $51.11 per share.


5,111


05/27/2015
9,800


 
Disposition at $50.58 per share.


495,684


05/27/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500


04/27/2015
10,000


 
Derivative/Non-derivative trans. at $1.35 per share.


13,500





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Arie S. Belldegrun 
Executive Chairman, President & CEO




Ms. Cynthia M. Butitta 
Chief Operating Officer




Mr. Paul L. Jenkinson 
CFO & Principal Accounting Officer




Dr. David D. Chang 
Chief Medical Officer, EVP-Research & Development




Dr. Jeffrey S. Wiezorek 
Senior Vice President-Clinical Development




Dr. Elizabeth A. Faust 
Vice President-Medical Affairs




Mr. Christopher  Nowers 
Head-Europe




Mr. Timothy L. Moore 
Executive Vice President-Technical Operations




Ms. Kimberly A. Metcalf 
VP-Customer Engagement, Training & Development




Ms. Helen Susan Kim 
EVP-Business Development




Dr. William Y. Go 
Senior Director-Clinical Development




Mr. Jeff  Aycock 
Senior Director-Clinical Operations




Ms. Shawn Cline Tomasello 
Chief Commercial Officer




Dr. Owen N. Witte 
Director




Mr. Joshua A. Kazam 
Director




Ms. Diane L. Parks 
Senior VP-Market Research, Sales & Marketing




Ms. Christine  Cassiano 
Senior VP-Communications & Investor Relations




Mr. Greg  Mann 
Vice President-Investor Relations




Dr. Rizwana F. Sproule 
Vice President-Regulatory Affairs




Dr. Franz B. Humer 
Independent Director




Mr. Ian T. Clark 
Independent Director




Mr. Steven B. Ruchefsky 
Independent Director




Mr. David  Bonderman 
Lead Independent Director




Mr. Jonathan M. Peacock 
Independent Director




Mr. Ran  Nussbaum 
Independent Director




Ms. Farah H. Champsi 
Independent Director




Mr. Roy  Doumani 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:43 AM EDT
July 22, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
10:39aWhy one analyst calls this the ‘chart of the week, month and potentially year’
10:07aThe cracked benchmark? Why some investors want a new standard for bonds
10:05a7 money-making lessons from the richest man who ever lived
10:03aGE’s stock falls as Jeff Immelt’s 64th and last quarter is another disappointment
10:01aNolan’s cinematic vision in ‘Dunkirk’ is Hollywood’s best defense against Netflix
9:59aAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
9:58aMicrosoft rides huge tax benefit from failing at smartphones to big earnings beat 
9:53aTrump says he has ‘complete power to pardon’
9:29aChipotle earnings: Media coverage of the latest illness scare will put earnings targets at risk
9:24aExxon earnings: Will stock trade higher on expected second-quarter beat?
9:20aPay TV expected to lose more than a million subscribers in latest quarter 
9:20aQualcomm’s issues go beyond Apple fight
9:20aYogaWorks IPO pulled on valuation concerns, not market conditions
9:18aAmazon’s foray into groceries means more mergers of food companies, experts say
9:00aThis is what should really worry you about stocks
8:26aEuro rally has room to run if this pattern continues to hold true
8:25aWeekend roundup: Companies that may cut dividends | FAANG stocks and market bubbles | Enjoy London on the cheap
8:25aAttention, shoppers: ‘Amazon effect’ is creating bargain stocks
8:25aWhy you might want to avoid these 30 dividend stocks
8:21aStocks brace for volatility in earnings deluge; Fed meeting looms 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































﻿






























Fox Run Management L.L.C. Takes Position in ITT Inc. (NYSE:ITT) - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for ITT Inc.

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor ITT Inc. with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

PPG Industries, Inc. (PPG) Shares Sold by Capstone Asset Management Co.
Check Point Software Technologies Ltd. (CHKP) Announces  Earnings Results
Stewart Information Services Corporation (NYSE:STC) Issues Quarterly  Earnings Results, Misses Estimates By $0.24 EPS
Skyworks Solutions, Inc. (NASDAQ:SWKS) Announces Quarterly  Earnings Results, Beats Expectations By $0.05 EPS
Tudor Investment Corp ET AL Buys New Stake in Public Storage (NYSE:PSA)
Zacks: Analysts Anticipate Ares Management L.P. (ARES) to Post $0.69 Earnings Per Share
Credit Suisse AG Sells 16,005 Shares of China Petroleum & Chemical Corporation (NYSE:SNP)
Barings LLC Has $385,000 Position in V.F. Corporation (VFC)
Capital One Financial Corporation (NYSE:COF) Shares Sold by Tudor Investment Corp ET AL
LKQ Corporation (NASDAQ:LKQ) Position Cut by Credit Suisse AG
Credit Suisse AG Lowers Stake in John Bean Technologies Corporation (NYSE:JBT)
AbbVie Inc. (ABBV) Rating Reiterated by Credit Suisse Group
$79.16 Million in Sales Expected for TrueCar, Inc. (NASDAQ:TRUE) This Quarter
Provident Trust Co. Holds Position in AbbVie Inc. (NYSE:ABBV)
Domtar Corporation (UFS) Stake Maintained by Barings LLC
Tudor Investment Corp ET AL Takes Position in National General Holdings Corp (NGHC)
Cooper-Standard Holdings Inc. (CPS) Shares Bought by Schwab Charles Investment Management Inc.
General Mills, Inc. (NYSE:GIS) Position Held by Bp Plc
Waste Management, Inc. (NYSE:WM) Position Increased by Vontobel Swiss Wealth Advisors AG
Helen of Troy Limited (HELE) Shares Bought by BlackRock Inc.







Fox Run Management L.L.C. Takes Position in ITT Inc. (NYSE:ITT)


					Posted by Lucas Kauffman on Jul 14th, 2017 // No Comments




Fox Run Management L.L.C. acquired a new position in  ITT Inc. (NYSE:ITT) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 13,700 shares of the conglomerate’s stock, valued at approximately $550,000. 
Other institutional investors also recently made changes to their positions in the company. World Asset Management Inc increased its position in shares of  ITT by 0.3% in the first quarter. World Asset Management Inc now owns 5,487 shares of the conglomerate’s stock worth $225,000 after buying an additional 19 shares during the last quarter.  United Capital Financial Advisers LLC increased its position in shares of  ITT by 0.6% in the first quarter. United Capital Financial Advisers LLC now owns 6,600 shares of the conglomerate’s stock worth $271,000 after buying an additional 42 shares during the last quarter.  Ladenburg Thalmann Financial Services Inc. increased its position in shares of  ITT by 3.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,378 shares of the conglomerate’s stock worth $131,000 after buying an additional 120 shares during the last quarter.  Baker Ellis Asset Management LLC increased its position in shares of  ITT by 0.5% in the first quarter. Baker Ellis Asset Management LLC now owns 25,349 shares of the conglomerate’s stock worth $1,040,000 after buying an additional 125 shares during the last quarter.  Finally, Albert D Mason Inc. increased its position in shares of  ITT by 0.7% in the first quarter. Albert D Mason Inc. now owns 30,329 shares of the conglomerate’s stock worth $1,244,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own  92.58% of the company’s stock. 


 Get ITT Inc. alerts:



Shares of ITT Inc. (NYSE:ITT) opened at 41.37 on Friday. The firm’s 50-day moving average price is $39.29 and its 200 day moving average price is $40.48. ITT Inc. has a 1-year low of $30.91 and a 1-year high of $44.00. The firm has a market cap of $3.67 billion, a PE ratio of 19.06 and a beta of 1.47. 





ITT (NYSE:ITT) last issued its quarterly earnings results on Monday, May 8th. The conglomerate reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. ITT had a return on equity of 14.65% and a net margin of 8.04%. The company had revenue of $625.80 million for the quarter, compared to analyst estimates of $607.08 million. During the same quarter in the prior year, the company posted $0.59 EPS. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year.  On average, equities research analysts forecast that  ITT Inc. will post $2.43 EPS for the current fiscal year. 
The company also recently announced a quarterly dividend, which was paid on Monday, July 3rd. Investors of record on Monday, June 12th were given a $0.128 dividend. This represents a $0.51 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend  was Thursday, June 8th. ITT’s dividend payout ratio (DPR) is currently 23.50%. 
COPYRIGHT VIOLATION NOTICE: This story was first  posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2017/07/14/fox-run-management-l-l-c-takes-position-in-itt-inc-nyseitt.html. 
A number of equities analysts recently commented on the company. TheStreet upgraded ITT from a “c+” rating to a “b” rating in a research report on Monday, March 27th. Stifel Nicolaus lifted their price objective on ITT from $49.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) downgraded ITT from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $46.00 to $43.00 in a research report on Tuesday, June 6th. ValuEngine upgraded ITT from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, BidaskClub upgraded ITT from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Two analysts have rated the stock with a hold rating and nine have assigned  a buy rating to the stock. The stock  has an average rating of “Buy” and a consensus price target of $46.67.
ITT Company Profile
ITT Corporation (ITT) is a diversified manufacturer of engineered critical components and technology solutions for industrial markets. The Company’s product and service offerings are organized in four segments: Industrial Process, Motion Technologies, Interconnect Solutions and Control Technologies. Industrial Process manufactures engineered fluid process equipment, and is a provider of plant optimization, solutions and aftermarket services and parts.







Receive News & Ratings for ITT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 














































Cynthia M Butitta - Santa Monica, CA | Intelius



























Sign In



We found Cynthia M Butitta in Santa Monica, CA


Cynthia M Butitta

                                                            Intelius found that Cynthia M Butitta  is  a female from Santa Monica, CA.  We have connected them to
                3 addresses,
                3 phones,
                and 0 relatives or associates.
         






Get Report Now

Cynthia Has Lived In

Santa Monica, CA
Sunnyvale, CA







Cynthia M Butitta



GenderFemale



Professional Status
Chief Operating Officer / Chief Financial Officer at Kite Pharma, Inc.



Get Report Now










Want to know more about Cynthia? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Cynthia, or use our people search engine to find others.
Get Background Check on Cynthia M Butitta
Get a Criminal Check on Cynthia M Butitta
Get a Public Record Report on Cynthia M Butitta
Get a People Search Report on Cynthia M Butitta


Cynthia M Butitta's Contact Information
Known Cities Lived In
Find out where Cynthia M Butitta has lived as well as Cynthia M Butitta's phone numbers and email addresses.




Cynthia M Butitta Has Lived in 1 States
California Address for Cynthia M Butitta


1755 E O**** A** 

Santa Monica, CA


Has Lived In

Santa Monica, CA
Sunnyvale, CA


Get Full Address Report










Phone Numbers Associated with Cynthia M Butitta

(310) ***-**** - Santa Monica, CA 
(408) ***-**** - Sunnyvale, CA 
(212) ***-**** - Santa Monica, CA 


Get Full Phone Report



Email Addresses Associated with Cynthia M Butitta

c******a@***.com
k*********h@***.com
c**b@***.com


Get Email Report




Cynthia M Butitta's Education Information
Known Schools Attended
Learn about Cynthia M Butitta's academic history.  Find out which schools Cynthia M Butitta attended, the dates attended as well as the degrees Cynthia M Butitta received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Cynthia M Butitta Has Attended 4 Schools
University of Wisconsin-Madison 1976 – 1978               Cynthia M Butitta has a MBA in Finance               
University of Wisconsin-Madison               1976 – 1978               Cynthia M Butitta has a MBA, Finance in Finance               
Edgewood College               1972 – 1976               Cynthia M Butitta has a Bs in Business and Accounting               
Edgewood College               1972 – 1976               Cynthia M Butitta has a Bs, Business and Accounting in Business and Accounting               


Cynthia M Butitta's Professional Information
Information regarding Cynthia M Butitta's professional history.  Find out previous places Cynthia M Butitta has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Cynthia M Butitta Has Worked at 11 Places
Company: Kite Pharma, Inc.
               Title: Chief Operating Officer / Chief Financial Officer
Company: Kite Pharma, Inc.
               Title: Chief Financial Officer
Cynthia M Butitta's Experience
Title: Chief Operating Officer / Chief Financial Officer
               Company: Kite Pharma, Inc.
Job Details
               Company Size: $10 mil to less than $25 mil - Employee Range: 100 to less than 500
Title: Chief Financial Officer
               Company: Kite Pharma, Inc.
Job Details
               Company Size: $10 mil to less than $25 mil - Employee Range: Less than 25
Additional Professional Information on Cynthia M Butitta

 See Cynthia M Butitta's LinkedIn Profile



Cynthia M Butitta's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Cynthia M Butitta


Cynthia M Butitta's known Social Networks And Potential Email Matches

Find all of Cynthia M Butitta's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Cynthia Butitta
Username Matches

                  CynthiaButitta
                  ButittaCynthia
                  Cynthia.Butitta
                  Butitta.Cynthia
                  Cynthia_Butitta
                  Butitta_Cynthia
                  Cynthia-Butitta
                  Butitta-Cynthia
                  CButitta
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
C Butitta







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.





















Butitta Cynthia M - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1222082 - Address: C/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 66 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


P%ret111110924-61-82-17P%wins1001001001000067S%ret2129-1-1-15-4-9-2S%wins62725763586062 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



7/11/17 17:367/10/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d201.3501515118D
7/11/17 17:367/10/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-1,546103.090-15-11118D
6/27/17 19:076/23/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.ad71.35054118D
6/27/17 19:076/23/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.ad-504100.810-5-4118D
6/27/17 12:256/23/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS-504100.810-5-4113D
6/12/17 19:166/9/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.350109118D
6/12/17 19:166/9/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-88588.550-10-8118D
4/27/17 18:494/25/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d201.35331515118D50757970-11114-1-2
4/27/17 18:494/25/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-1,22881.8533-15-11118D50757970-11114-1-2
4/4/17 16:154/3/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d71.353354118D4556407442-750-247
4/4/17 16:154/3/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-41081.9633-5-4118D4556407442-750-247
3/28/17 19:573/27/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533109118D36804370455-720-15
3/28/17 19:573/27/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-77777.6733-10-8118D36804370455-720-15
3/10/17 17:253/9/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d291.35332122118D256634606850161120-7
3/10/17 17:253/9/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-1,70680.7833-21-15118D256634606850161120-7
3/1/17 21:592/27/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.dm521.35333949118D858214049343034-6-7-1
3/1/17 21:592/27/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.dm-2,85673.4633-39-25118D858214049343034-6-7-1
2/1/17 19:091/31/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533109118D-244-1114-2-185-114457
2/1/17 19:091/31/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-50650.5633-10-8118D-244-1114-2-185-114457
1/10/17 17:031/6/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533109118D-27-49-730126-5-8152
1/10/17 17:031/6/17KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-50150.1333-10-8118D-27-49-730126-5-8152
12/22/16 16:4812/20/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS-12650.8633-2-393D-9-21-8-11-1-42-64-2463
11/29/16 17:0211/25/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533101295D13-44-6-17-26-4-6410-663
11/29/16 17:0211/25/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-50450.4033-10-995D13-44-6-17-26-4-6410-663
11/14/16 18:5711/10/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533101295D24-3514-18-7112213-3-1-114
11/14/16 18:5711/10/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-50650.6533-10-995D24-3514-18-7112213-3-1-114
9/28/16 17:039/26/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533101295D114113618-3-249-1-3-18-1537
9/28/16 17:039/26/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-54154.1333-10-995D114113618-3-249-1-3-18-1537
8/26/16 18:388/25/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533101295D12012222119-1-6-5-10-6-13-3
8/26/16 18:388/25/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-58358.2833-10-995D12012222119-1-6-5-10-6-13-3
7/26/16 19:037/25/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.d141.3533101295D121-2535107341016-10-8
7/26/16 19:037/25/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.d-50950.9433-10-995D121-2535107341016-10-8
6/27/16 19:086/23/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOM.dm271.3533202795D72-17-201719-12-3033510-6
6/27/16 19:086/23/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOOS.dm-1,01450.7133-20-1795D72-17-201719-12-3033510-6
4/6/16 19:064/4/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101295D-10-19-191011189-4-6-20-5344
4/6/16 19:064/4/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-50050.0033-10-995D-10-19-191011189-4-6-20-5344
3/3/16 19:133/1/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101295D-121-35-43115145-5-6-21343
3/3/16 19:133/1/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-50050.0333-10-995D-121-35-43115145-5-6-21343
2/4/16 21:062/2/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d31.35332294D-28-38-37-28-9-8-4-12-1416-82611
2/4/16 21:062/2/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-9550.1333-2-294D-28-38-37-28-9-8-4-12-1416-82611
1/29/16 18:151/27/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d111.35338994D-37-37-37-30-18-18-103-1-6-2162
1/29/16 18:151/27/16KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-41851.6233-8-894D-37-37-37-30-18-18-103-1-6-2162
12/29/15 19:1712/28/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101294D14514-24-14-7-1-2-3-31-32-21-26
12/29/15 19:1712/28/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-61661.5633-10-1094D14514-24-14-7-1-2-3-31-32-21-26
11/30/15 20:2311/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d201.3533152576D1015955331782-8-14-21-36-36-39
11/30/15 20:2311/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-1,29786.4533-15-1776D1015955331782-8-14-21-36-36-39
11/12/15 18:3311/10/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d71.35335776D9256364320131129-18-45-46-35
11/12/15 18:3311/10/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-40080.0033-5-676D9256364320131129-18-45-46-35
10/28/15 19:1710/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101576D973001310105-4222-37-35-36
10/28/15 19:1710/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-69969.9133-10-1276D973001310105-4222-37-35-36
9/30/15 19:019/28/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101576D80-10-15-11-7-21-142143016-192
9/30/15 19:019/28/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-55955.8733-10-1276D80-10-15-11-7-21-142143016-192
8/28/15 19:078/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101576D100-17-1-26-21-711-5-7-457-205
8/28/15 19:078/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-53653.6233-10-1276D100-17-1-26-21-711-5-7-457-205
7/28/15 19:037/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101575D213-425187-7-5-10-32-2-30-29
7/28/15 19:037/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-68568.4833-10-1275D213-425187-7-5-10-32-2-30-29
7/1/15 19:156/29/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101575D11196194-2-13-413-191-20
7/1/15 19:156/29/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-59759.6533-10-1275D11196194-2-13-413-191-20
5/29/15 18:565/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.d141.3533101575D14-22-19-613-1-1-110-757-14
5/29/15 18:565/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS.d-50650.5933-10-1275D14-22-19-613-1-1-110-757-14
4/29/15 21:544/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOM.ad141.3533101575D65-26-13-6-15-10-8-2-43127-15
4/29/15 17:484/27/15KITEKite Pharma, Inc.DEHealthBioPrdBiological Products, (No DiagButitta Cynthia MCAOCOO,CFOS-59859.7633-10-1365D65-26-13-6-15-10-8-2-43127-15
8/11/06 14:108/10/06TELKTelik IncDEHealthDrugPharmaceutical PreparationsButitta Cynthia MCAOCOO,CFOP7715.47951637D-71-17-4-3-7-6-2110924-61-82
3/16/05 20:453/16/05TELKTelik IncDEHealthDrugPharmaceutical PreparationsButitta Cynthia MCAOCOO,CFOM.d383.8112104731D50-30-21-14-9-4-4-1436-8327
10/15/04 13:2810/14/04TELKTelik IncDEHealthDrugPharmaceutical PreparationsButitta Cynthia MCAOCOO,CFOM.d142.001275619D46-15-28-6-10-9-10-72-49-2-14-22
9/16/04 21:079/16/04TELKTelik IncDEHealthDrugPharmaceutical PreparationsButitta Cynthia MOCOO,CFOS-21621.5714-10-4512D60-3-16014143-12-3-10-3-28-23



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.




 


Cynthia Butitta | Professional Profile
 


























 









LinkedIn



















































Main content starts below.




Cynthia ButittaConsultant and Board MemberLocationSan Francisco Bay AreaIndustryBiotechnologyCurrentKite Pharma, Inc., Silicon Valley Directors' ExchangePreviousNextWave Pharmaceuticals Inc., Telik, Inc., Connetics CorporationEducationUniversity of Wisconsin-Madison238 connectionsView Cynthia’s full profile. It's free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Cynthia’s Full ProfileCynthia’s ActivityNeon is number 3 on the list!
Steve Montgomery , Bill...Cynthia sharedSummaryCynthia Butitta is an experienced fiscal and operational executive with over 25 years of progressively responsible experience in both the biotechnology and high technology industry. A detailed oriented forward-thinker adept at building organizations to drive profitability and facilitate growth. Diverse leader demonstrating strong fund raising, strategic, analytical, negotiation, communication and problem-solving abilities in both a start-up environment and large Fortune 100 companies.Specialties: Mergers and Acquisitions, IPO Experience, Strategic Planning, Operations Management, SEC Reporting, SOX Compliance, Business Development, Investor Relations, Regulatory, Commercial OperationsExperienceChief Operating Officer and Chief Financial OfficerKite Pharma, Inc.December 2013  –  Present (3 years 8 months)Board MemberSilicon Valley Directors' Exchange2008  –  Present (9 years)SVP, Chief Financial OfficerNextWave Pharmaceuticals Inc.March 2011  –  December 2012 (1 year 10 months)Chief Operating Officer and Chief Financial OfficerTelik, Inc.1998  –  2010 (12 years)Operations Management, Strategic Planning, Private and Public Financings, SEC Reporting, SOX Compliance, Investor Relations, Commercial Operations, Business Development, Information TechnologyChief Financial Officer and Vice-President, Finance and AdministrationConnetics Corporation1995  –  1997 (2 years)IPO Experience, Investor Relations, SEC Reporting, Information TechnologyChief Financial Officer and Vice-President, Finance and AdministrationInSite Vision, Inc.1994  –  1995 (1 year)Strategic Planning, Corporate Communications, Mergers and Acquisitions, Human Resource Managment, SEC ReportingFinance Director, Sales and SupportTandem Computers1993  –  1994 (1 year)Financial Planning, Order Administration, Credit and CollectionsVice President, Finance and Corporate ControllerMips Computer Systems, Inc.1988  –  1992 (4 years)Finance, Accounting, Tax and Treasury, Order Administration, Sales Compensation AdministrationSkillsStrategic PlanningSarbanes-Oxley ActMergersStrategySEC filingsIPOBusiness DevelopmentBiotechnologyMergers & AcquisitionsStart-upsVenture CapitalLeadershipManagementMedical DevicesBusiness StrategySee 12+Strategic Financial PlanningInvestor RelationsExecutive ManagementCross-functional Team LeadershipAccountingFinanceAcquisition IntegrationBusiness PlanningCorporate DevelopmentFinancial ModelingSEC FilingsFinancial PlanningSee lessHow's this translation?Great•Has errorsThanks for your help!EducationUniversity of Wisconsin-MadisonMBA, FinanceMBA, Finance1976  –  1978Edgewood CollegeBS, Business and AccountingBS, Business and Accounting1972  –  1976Graduated summa cum laudeGroupsUCLA Anderson - Executive EducationView Cynthia’s full profile to...See who you know in commonGet introducedContact Cynthia directlyView Cynthia’s Full ProfileNot the Cynthia you’re looking for? View moreView this profile in another languageEnglishGermanPeople Also ViewedFrank EspositoAssistant General Counsel and Corporate Secretary at OMNOVA SolutionsKimi IguchiChief Financial Officer at Sage TherapeuticsDaniel J. O'ConnorCEO at Advaxis, Inc.Kyle KuvalankaChief Operating Officer at Syros PharmaceuticalsJason BraunClaudia J. MerkleExperienced Financial Services Executive, Commitment to tranforming obstacles into creative solutionsShalini SharpJesus VarelaMardi DierCFO at Portola PharmaceuticalsNick LeschlyCEO at bluebird bioPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Cynthia ButittaFirst NameLast NameExample:  Cynthia ButittaCynthia ButittaCOO and CFO at Telik, Inc.United StatesCynthia Butitta--United StatesMore professionals named Cynthia ButittaLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country




















